<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>ANTIBACTERIAL CHEMOTHERAPEUTICS SUFLOAMIDES,QUINOLONES</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,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)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\19.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>ANTIBACTERIAL CHEMOTHERAPEUTICS SUFLOAMIDES,QUINOLONES <a name='18:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	
<p>
<img src="./Pharmacology/pasted_image.png">]<br>
→ <i>Naladixic acid </i>is the predecessor to all fluroquinolones<br>
→ <i>Norfloxacin </i> the first fluorinated quinolone<br>
<ul style='padding-left: 30pt'>
<li>rapidly followed by the development of <i>ciprofloxacin</i></li>
</ul>
→ NEW COMPOUNDs<br>
<ul style='padding-left: 30pt'>
<li>offer greater potency</li>
<li>broader spectrum of antimicrobial activity </li>
<li>better safety profile than older quinolones and antibiotics</li>
</ul>
</p>

<h1>1.α.MECHANISM OF ACITON</h1>

<p>
→ enter the bacterium<br>
<ul style='padding-left: 30pt'>
<li>by passive diffusion </li>
</ul>
→ through water-filled protein channels (porins) in the outer membrane<br>
→ inhibit the replication of bacterial DNA<br>
<ul style='padding-left: 30pt'>
<li>by interfering with the action of DNA gyrase (topoisomerase II)</li>
<li>topoisomerase IV  — required by bacteria for cell division — during bacterial growth &amp; reproduction</li>
</ul>
[Topoimerases are enzymes that <br>
<ul style='padding-left: 30pt'>
<li>change the configuration or topology of DNA]</li>
</ul>
→ G- [Escherichia coli] → inhibit DNA-gyrase is more significant than that of topoisomerases IV<br>
<ul style='padding-left: 30pt'>
<li>in G+ [streptococci] the opposite is true.</li>
</ul>
→ 
</p>

<h1>1.b.ANTIMICROBIAL SPECTRUM</h1>

<p>
→ Bactericidical activiy becomes more pronoucned<br>
<ul style='padding-left: 30pt'>
<li>as the serum drug concentration increases to approx. 30-fold</li>
</ul>
→ In general effective against<br>
<ul style='padding-left: 30pt'>
<li>G- such as</li>
<li>Enterobacteriaceae , Pseudomonas species , Haemophilus influnzae , Moraxella catarrhalis etc</li>
<li>gonorrhe but not syphilis</li>
</ul>
newer agents → <i>Levofloxacin/Moxifloxacin--&gt;[against anaerobes &amp; G+]</i><br>
<ul style='padding-left: 30pt'>
<li>good activity against some G+ such as
<ul>
<li>Streptococus pneumonieae</li>
</ul></li>
</ul>
→ nonfluorinated quinolone <i>nalidixic acid </i>→ urinary tract<br>
→ <i>Ciprofloxacin / norfloxacin</i><br>
<ul style='padding-left: 30pt'>
<li>against aerobic G- and atypical bacteria</li>
<li>exhibit significant intracellular penetration</li>
</ul>
→ <i>Levofloxacin</i><br>
<ul style='padding-left: 30pt'>
<li>↑ activity against G</li>
<li><img src="./Pharmacology/pasted_image001.png"></li>
</ul>
</p>

<h1>1.c.Examples of clinically useful fluoroquinolones</h1>

<p>
<img src="./Pharmacology/pasted_image004.png">
</p>

<h1>1.Ciprofloxacin</h1>

<p>
→ against many systemeic infecitons<br>
<ul style='padding-left: 30pt'>
<li>with exception cuzed by methicilin-resistant [Staphylococcus aureus](MRSA)</li>
<li>enterococci</li>
<li>pneumonococci</li>
<li>traveler diarreha caused by E.coli.</li>
<li>is the most potent of the fluoroquinolones for Pseudomonas aeruginosa</li>
<li>as an alternative to amimoglycosides</li>
<li>may act synergastically with β-lactams</li>
<li>typhoid fever in thrid-world countires</li>
</ul>
</p>

<h1>2.NORFLOXACIN</h1>

<p>
→ effective against both G-(including P.aeruginos and G+ (complicated and uncomplicated UTIs,prostatitits,traveler diarrhea(unlabeled use)<br>
→ is not effective against systemic infenciton
</p>

<h1>3.Levofloxacin</h1>

<p>
→ is an isomer of olfoxacin<br>
→ treatment of <br>
<ul style='padding-left: 30pt'>
<li>prostatis due to E .coli</li>
<li>sexually transmittied diseases [exception of syphilis]</li>
<li>alternative therapy in patients with gonorrhe</li>
</ul>
→ broad spectrum of activity [wide range of infenctions]<br>
<ul style='padding-left: 30pt'>
<li>skin infenction</li>
<li>acute sinusitis</li>
<li>actue exacerbation of chronic bronchitis</li>
<li>community-asquired pneumonia</li>
<li>excellent activity against S.pneumoniae respiratory infenctions.</li>
</ul>
</p>

<h1>4.Moxifloxacin</h1>

<p>
→ enhanced activity against G+<br>
→ excellent activity against anaerobes<br>
→ very poor activity against P.aeruginosa<br>
→ does not concentrate in urine <br>
<ul style='padding-left: 30pt'>
<li>thus is not indicated for UTI's</li>
</ul>
</p>

<h1>1.d.Resistane</h1>

<p>
→ no plasmid-mediated resistance has been reported<br>
→ MRSA, pseudomonas , coagulase negative staphylococci ,enterococci<br>
<ul style='padding-left: 30pt'>
<li>emerged due to chromosomal muatation.</li>
</ul>
A.<b>Alerted target</b><br>
<ul>
<li>mutation in the baceterial DNA gyrase
<ul>
<li>↓ affinity of fluoroquinolones</li>
</ul>
</li>
<li>topoisomerase IV also undergoes mutation.</li>
</ul>
B.↓ accumulation:<br>
<ul>
<li>↓ intracellular concentration of the drugs in the bacterial cells linked to two mechanism</li>
<li>↓ number of porin proteins in the outer membrane of the resistant cell</li>
<li>other mechanism associated with an energy-dependent efflux system in the cell membrane.</li>
</ul>
</p>

<h1>1.e.Pharmacokinetics</h1>

<p>
1.Absorption<br>
<ul style='padding-left: 30pt'>
<li>35-70% orally admin. of <i>Norfloxacin </i>is absorbed.</li>
<li>85-95% orally admin. of other fluoroquinolones</li>
</ul>
→ ingestion of the fluoroquinolones with<br>
<ul style='padding-left: 30pt'>
<li>sucralfate</li>
<li>antacids containing zinc,aluminum,magnesium</li>
</ul>
<ul>
<li>interfere with the absorption of these antibacterial drugs.</li>
</ul>
2.Elimination<br>
→ binding to plasma proteins 10-40%<br>
→ all fluroqu distribute well <br>
<ul style='padding-left: 30pt'>
<li>into all tissues and body fluids.</li>
<li>high in bone,urine,kidney,prostatic tissue</li>
</ul>
→ CFS relatively low [except for ofloxacin]<br>
→ also accumulates in macrophages and polymorphonuclear leukocytes<br>
→ most excrected renally<br>
<ul style='padding-left: 30pt'>
<li>primarly by the liver,</li>
</ul>
→ no dose adjustment is required with ↓ renal functioning.
</p>

<h1>1.f.Adverse Reactions</h1>

<p>
→ in general are very well tolerated<br>
→ nausea , vommiting , diarrhea <br>
→ headache , dizziness , epilepsy , <br>
→ phototoxicity  <br>
→ Contraindicated<br>
<ul style='padding-left: 30pt'>
<li>prolong QTc interval [arrythmias  or patients taking antiarrythmics]</li>
</ul>
→ Drug interaction<br>
<ul style='padding-left: 30pt'>
<li>antacis &amp; cations</li>
<li>theophylline [by inhibiting its metabolism]</li>
</ul>
</p>

<br>

<h1>III.SULFONAMIDES</h1>

<br>

<h1>III.A.Mechanism of action</h1>

<p>
→ synthetic analgos of PABA<br>
→ compete with PABA subtrate for the bacterial enzymes<br>
<ul style='padding-left: 30pt'>
<li>dihydropteroate sythesase</li>
</ul>
→ they inhibit the synthesis of bacterial<br>
<ul style='padding-left: 30pt'>
<li>dihydrofolic acid</li>
<li>and the formation of cofactor form.</li>
</ul>
→ sufla's [including <i>cotrimoxazole] </i> are — bacteriostatic — 
</p>

<h1>III.B.Antibacterial spectrum</h1>

<p>
→ against selected Enterobacteria in the urinary tract<br>
→ <i> Sulfadiazine </i>in combo with <i>dihydrofolate reductase inhibitor Pyrimethamine</i><br>
<ul style='padding-left: 30pt'>
<li>is preffered against toxoplasmosis.</li>
</ul>
</p>

<h1>III.C.Resistance</h1>

<p>
→ only organism that synthesize their folate de novo are sensitive to sulfamides<br>
<ul style='padding-left: 30pt'>
<li>humans who synthesize critical folate cofactors from dietary folic acid are not affected</li>
<li>bacteria can obtain folates from their enviroments are naturally resistant to these drugs.</li>
</ul>
→ plasmid tranfers or random mutation.<br>
[Organisms resistant to one member of this drug family are resistant to all]<br>
→ due to <br>
<ul style='padding-left: 30pt'>
<li>alerted dihydropteroate synthase</li>
<li>decreased cellurlar permability to sulfa drugs</li>
<li>enhanced production of the natural substrate,Paba</li>
</ul>
</p>

<h1>III.D.Pharmacokinetics</h1>

<p>
1.ADMINISTRATION<br>
→ most of them well absorbed after oral admin. via the small intestine<br>
→ [sulfasalazine]- in intestinal flora splitted into<br>
<ul style='padding-left: 30pt'>
<li><i>sulfapyridine and 5-aminosalicylate </i></li>
</ul>
→ because of risk of sensitizatin does not applied topically<br>
→ <i>Silver sulfonamide or mafenide / acetate</i><br>
<ul style='padding-left: 30pt'>
<li>have been effective in ↓ burn-associated sepsis</li>
</ul>
2.DISTRIBUTION<br>
→ bound to serum albumin in the circulation<br>
→ extent of binding depends on the particular agent's pKa<br>
→ thought body water<br>
→ penatrate well CFS<br>
→ can also pass placental barrier and enter fetal tissues
</p>

<p>
3.EXCRETION<br>
→ eliminated by glomerular filtration and require close adjustments for renal dysfunction<br>
→ depressed kideny funciton<br>
<ul style='padding-left: 30pt'>
<li>cause accumulation of both the parent compounds</li>
<li>may also be eliminated on the breast milk</li>
</ul>
</p>

<h1>III.E.Adverse Effects</h1>

<p>
1.CRYSTALOURIA<br>
<ul style='padding-left: 30pt'>
<li>nephrotoxicity</li>
<li><i>sulfisoxazole+sulfamethaxazole  = </i>are more soluble at urinary pH than the older sulfonamides (<i>sulfadiazine)</i></li>
</ul>
2.HYPERSENSITIVITY<br>
<ul style='padding-left: 30pt'>
<li>rashes</li>
<li>angioedema</li>
<li>Steven-Johnson syndrome</li>
</ul>
3.HEMOPOETIC DISTRUBANCES<br>
<ul style='padding-left: 30pt'>
<li>hemolytic anemia (in patients with 6-phosphate dehydrogenase deficiency)</li>
</ul>
4.DRUG POTENTIATION<br>
<ul style='padding-left: 30pt'>
<li>of the anticoagulant effect of warfarin</li>
</ul>
<ul>
<li>which results from displacements from binding sites on serum albumin.</li>
</ul>
→ free <i>methotrexate </i>levels may also rise<br>
5.KERNICTERUS<br>
→ disorder may occur in newborn<br>
<ul style='padding-left: 30pt'>
<li>diplace bilirubin from binding sites on serum albumin</li>
<li>bilirubin is the free to pas into the CNS,because the baby's blood-brain barrier is not fully developed.</li>
</ul>
6.CONTRAINDICATION<br>
<ul style='padding-left: 30pt'>
<li>newborns and infant less than 2months (risk of kernicterus)</li>
<li>should not be given to patients receiving <i>methenamine [</i> for UTI's]--&gt; (because condense with formaldehyde)</li>
</ul>
</p>

<h1>IV.TRIMETHOPRIM</h1>

<p>
→ potent inhibitor of bacterial dihydrofolate reductase<br>
<ul style='padding-left: 30pt'>
<li>antibacterial spectrum similar to other sulfonamides</li>
</ul>
→ most often coumpounded with <i>sulfamethoxazole </i><br>
<ul style='padding-left: 30pt'>
<li>producing the combination called <i>Cortimoxazole.</i></li>
</ul>
</p>

<h1>IV.A.Mechanism of action</h1>

<p>
→ active form of folate<br>
<ul style='padding-left: 30pt'>
<li>tetrahydro-derivative that is formed through the reduction of </li>
<li>dihydrofolic acid by dihydrofolate reductase.</li>
</ul>
→ enzymatic reactions is inhibited by <i>trimethoprim</i><br>
<ul style='padding-left: 30pt'>
<li>decreasing availability of the tetrahydrofolate coenzymes.</li>
<li>required for purine,pyrimide, amino acid synthesis.</li>
</ul>
</p>

<h1>IV.B.Antibacterial spectrum</h1>

<p>
→ similar to that of sulfamethaxazole<br>
→ 20 to 50-fold  more potent than the sulfonamide<br>
→ may be used alone to treat acute  UTI's and treatment of bacterial prostatis.
</p>

<br>

<p>
etc<br>
<img src="./Pharmacology/pasted_image002.png"><img src="./Pharmacology/pasted_image003.png">
</p>

<br>

<h1>V.Cotrimoxazole</h1>

<p>
→ trimehtoprin + sulfamethoxazole  combination<br>
<ul style='padding-left: 30pt'>
<li>shows greater antimicrobial acitvity than of either drugs used alone</li>
</ul>
</p>

<h1>V.A.Mechanism of action</h1>

<p>
→ sygergy arise from<br>
<ul style='padding-left: 30pt'>
<li>inhibition of two sequential steps in the synthesis of tetrahydrofolic acid
<ul>
<li>sulfamethoxazole inhibits the incorporation of PABA into dihydrofolic acid precursors</li>
</ul>
</li>
<li>and trimethoprim prevents reduction of dihydrofolate to tetrahydrofolate.</li>
</ul>
</p>

<h1>V.B.Antibacterial spectrum</h1>

<p>
→ broader spectrum of antibacterial action than the sulfa drugs<br>
→ effective on treating UTIs and respiratory tract infenciton<br>
→ activity versus MRSA<br>
<ul style='padding-left: 30pt'>
<li>community ascquired skin and soft tissues infenctions.</li>
</ul>
</p>

<h1>V.C.Resistance</h1>

<p>
→ is less frequently encountered than resistance to either of the drugs alone
</p>

<h1>V.D.Pharmacokientics</h1>

<p>
→ trimethoprim is more lipid soluble than sulfamethoxazole <br>
<ul style='padding-left: 30pt'>
<li>and also has a greater voluem of distribution</li>
</ul>
→ one part of trimethorpin to five parts of the sulfa drugs produces<br>
<ul style='padding-left: 30pt'>
<li>a ratio in the plasma on twenty parts sulfamethaxazole to one part trimethoprim.</li>
</ul>
→ this ratio is optimal for antibiotic effect.<br>
→ generally admin. orally<br>
→ both drugs and their metabolites are excreted in the urine.
</p>

<h1>V.E.Adverse effects</h1>

<p>
→ reaction involving skin is very common and may be severe in eldelry<br>
→ nause , vomiting, glossitis  and stomatitis [are not usual ]<br>
→ megaloplastic anemia , leukopenia , thrombocytopenia	<br>
<ul style='padding-left: 30pt'>
<li>all these effects may preversed by the concurrent admin. of folinic acid [does not enter the microorganism]</li>
</ul>
</p>

<p>
→ Prolonged prothrobin times in patients receign both sulfamethoxazole and warfarin have been reported<br>
→ plasma half-life of penytoin may be increased [due to inhibition of its metabolism]<br>
→ methotrexate levels may rise due to displacement from albumin-binding site by sulfamethoxazole.
</p>

<p>
<img src="./Pharmacology/pasted_image005.png"><img src="./Pharmacology/pasted_image006.png"><img src="./Pharmacology/pasted_image007.png">
</p>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>104kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>138kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>20.8kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image003.png'>pasted_image003.png</a></td><td>&nbsp;</td><td>41.9kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image004.png'>pasted_image004.png</a></td><td>&nbsp;</td><td>36.1kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image005.png'>pasted_image005.png</a></td><td>&nbsp;</td><td>145kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image006.png'>pasted_image006.png</a></td><td>&nbsp;</td><td>135kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image007.png'>pasted_image007.png</a></td><td>&nbsp;</td><td>44.0kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
